Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A McNeil

Showing results (311-320 of 365) with videos related to

Pageof 37
Sort By:
Emerging Infectious Diseases|February 25, 2020
Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada<sup>1</sup>Joanne M Langley, Soren Gantt, Caroline Quach, et al.
Vaccine|November 26, 2011
Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous doseScott A Halperin, David Scheifele, Gaston De Serres, et al.
Human Vaccines & Immunotherapeutics|July 11, 2013
Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparisonDavid W Scheifele, Shelly A McNeil, Brian J Ward, et al.
Vaccine|March 29, 2017
Knowledge, attitudes, beliefs, and behaviors of university students, faculty, and staff during a meningococcal serogroup B outbreak vaccination programD M MacDougall, J M Langley, L Li, et al.
The Lancet. Infectious Diseases|August 11, 2019
Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trialKathleen M Mullane, Vicki A Morrison, Luis H Camacho, et al.
Vaccine|March 8, 2012
Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulationsAmeneh Khatami, Matthew D Snape, Elizabeth Davis, et al.
Vaccine|April 3, 2019
Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trialsMarta López-Fauqued, Laura Campora, Frédérique Delannois, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|February 14, 2015
Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network, January 2015S A McNeil, M K Andrew, L Ye, et al.
The Journal of Hospital Infection|January 20, 2020
Sources of viral respiratory infections in Canadian acute care hospital healthcare personnelS Buckrell, B L Coleman, S A McNeil, et al.
Open Forum Infectious Diseases|January 12, 2023
Burden of Severe Illness Associated With Laboratory-Confirmed Influenza in Adults Aged 50-64 Years, 2010-2011 to 2016-2017Philip Kim, Brenda Coleman, Jeffrey C Kwong, et al.
Pageof 37

Showing results (311-320 of 365) with videos related to

Sort By:
Pageof 37
Emerging Infectious Diseases|February 25, 2020
Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada<sup>1</sup>Joanne M Langley, Soren Gantt, Caroline Quach, et al.
Vaccine|November 26, 2011
Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous doseScott A Halperin, David Scheifele, Gaston De Serres, et al.
Human Vaccines & Immunotherapeutics|July 11, 2013
Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparisonDavid W Scheifele, Shelly A McNeil, Brian J Ward, et al.
Vaccine|March 29, 2017
Knowledge, attitudes, beliefs, and behaviors of university students, faculty, and staff during a meningococcal serogroup B outbreak vaccination programD M MacDougall, J M Langley, L Li, et al.
The Lancet. Infectious Diseases|August 11, 2019
Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trialKathleen M Mullane, Vicki A Morrison, Luis H Camacho, et al.
Vaccine|March 8, 2012
Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulationsAmeneh Khatami, Matthew D Snape, Elizabeth Davis, et al.
Vaccine|April 3, 2019
Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trialsMarta López-Fauqued, Laura Campora, Frédérique Delannois, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|February 14, 2015
Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network, January 2015S A McNeil, M K Andrew, L Ye, et al.
The Journal of Hospital Infection|January 20, 2020
Sources of viral respiratory infections in Canadian acute care hospital healthcare personnelS Buckrell, B L Coleman, S A McNeil, et al.
Open Forum Infectious Diseases|January 12, 2023
Burden of Severe Illness Associated With Laboratory-Confirmed Influenza in Adults Aged 50-64 Years, 2010-2011 to 2016-2017Philip Kim, Brenda Coleman, Jeffrey C Kwong, et al.
Pageof 37